<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="206174">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00404586</url>
  </required_header>
  <id_info>
    <org_study_id>BGS105049</org_study_id>
    <nct_id>NCT00404586</nct_id>
  </id_info>
  <brief_title>Effects Of Single Doses Of GW784568X On Allergic Rhinitis Symptoms In Male Subjects Whilst In An Environmental Chamber</brief_title>
  <official_title>A Randomised, Placebo-controlled, 4-period, Incomplete Block, Crossover Study of 7 Days Dosing of Intranasal GW784568X (100mcg, 200mcg and 400mcg od), Fluticasone Propionate (200mcg od) and Placebo (Blinded for GW784568X vs Placebo) to Evaluate the Efficacy and Safety Using an Environmental Chamber in Male Subjects With Allergic Rhinitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      This study was designed to look at safety aspects and effects of intranasal doses of
      GW784568X on allergic rhinitis symptoms to develop this drug for its use in people who
      suffer with allergic rhinitis
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomised, placebo-controlled, 4-period, incomplete block, crossover study of 7 days
      dosing of intranasal GW784568X (100mcg, 200mcg and 400mcg od), fluticasone propionate
      (200mcg od) and placebo (blinded for GW784568X vs placebo) to evaluate the efficacy and
      safety using an environmental chamber in male subjects with allergic rhinitis
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">January 2007</completion_date>
  <primary_completion_date type="Actual">January 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double-Blind</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Nasal symptom scores after 7 days of dosing</measure>
    <time_frame>after 7 days of dosing</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Nasal symptom scores Eye symptom scores Other symptom scores Nasal secretion and airflow on Day 7 and Day 8 after being exposed to allergen</measure>
    <time_frame>on Day 7 and Day 8</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">45</enrollment>
  <condition>Allergic Rhinitis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GW784568X</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Healthy with exception of seasonal rhinitis. May also have mild asthma.

          -  Weight greater than or equal to 50kg

          -  Non-smoker for at least 12 months

        Exclusion criteria:

          -  History of frequent nosebleeds

          -  Have participated in another trial in the last 30 days.

          -  Have donated blood in the previous 3 months

          -  Have used prescription or non prescription drugs within last 7 days

          -  Have history of alcohol/drug abuse within last 12 months

          -  Have positive Hepatitis B or C test within 3 months of screening

          -  Subject tested positive for HIV
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials, MD</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 18, 2017</lastchanged_date>
  <firstreceived_date>November 27, 2006</firstreceived_date>
  <responsible_party>
    <name_title>Study Director</name_title>
    <organization>GSK</organization>
  </responsible_party>
  <keyword>GW784568X</keyword>
  <keyword>Intranasal</keyword>
  <keyword>Environmental Challenge Chamber</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Rhinitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
